title: Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis.
abstract: We report a successful case of sirolimus treatment for chylous pleural and peritoneal effusions of lymphangioleiomyomatosis after lung transplantation. A 32-year-old woman underwent living donor lung transplantation. Persistent chylous pleural and peritoneal effusions were seen postoperatively. Pleurodesis by intrathoracic injection of OK-432, minomycin, and somatostatine analog failed to control chylous effusions. However, sirolimus treatment reduced the amount of chylous drainage and improved both chylous pleural and peritoneal effusions.
authors.affiliation: Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Ohara
authors.forename: Takahiro
authors.initials: T
authors.lastname: Oto
authors.forename: Kentaro
authors.initials: K
authors.lastname: Miyoshi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tao
authors.forename: Masaomi
authors.initials: M
authors.lastname: Yamane
authors.forename: Shinichi
authors.initials: S
authors.lastname: Toyooka
authors.forename: Megumi
authors.initials: M
authors.lastname: Okazaki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Date
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Sano
mesh_terms: D000284:Administration, Oral; D000328:Adult; D002916:Chylothorax / Q000188:drug therapy* / Q000209:etiology; D002915:Chylous Ascites / Q000188:drug therapy* / Q000209:etiology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000175:diagnosis / Q000601:surgery; D016040:Lung Transplantation / Q000009:adverse effects* / Q000379:methods; D018192:Lymphangioleiomyomatosis / Q000175:diagnosis / Q000601:surgery; D011183:Postoperative Complications / Q000175:diagnosis / Q000188:drug therapy; D018570:Risk Assessment; D020123:Sirolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus